JP2021504726A - Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 - Google Patents
Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 Download PDFInfo
- Publication number
- JP2021504726A JP2021504726A JP2020546259A JP2020546259A JP2021504726A JP 2021504726 A JP2021504726 A JP 2021504726A JP 2020546259 A JP2020546259 A JP 2020546259A JP 2020546259 A JP2020546259 A JP 2020546259A JP 2021504726 A JP2021504726 A JP 2021504726A
- Authority
- JP
- Japan
- Prior art keywords
- pmvk
- cancer
- protein
- expression level
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04002—Phosphomevalonate kinase (2.7.4.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91235—Phosphotransferases in general with a phosphate group as acceptor (2.7.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
Claims (24)
- ホスホメバロン酸キナーゼ(PMVK)タンパク質またはそれをコーディングする遺伝子を有効成分として含む放射線抵抗性癌診断用バイオマーカー組成物。
- 前記癌は、肺癌または膵臓癌であることを特徴とする請求項1に記載の放射線抵抗性癌診断用バイオマーカー組成物。
- PMVKの発現レベルを測定することができる製剤を有効成分として含む放射線抵抗性癌診断用組成物。
- 前記PMVKの発現レベルを測定することができる製剤は、前記PMVK遺伝子に特異的に結合するプライマーまたはプローブ、前記PMVKタンパク質に特異的に結合する抗体、ペプチド、アプタマーまたは化合物であることを特徴とする請求項3に記載の放射線抵抗性癌診断用組成物。
- 前記癌は、肺癌または膵臓癌であることを特徴とする請求項3に記載の放射線抵抗性癌診断用組成物。
- 請求項3から請求項5のうち何れか一項に記載の組成物を含む放射線抵抗性癌診断用キット。
- ホスホメバロン酸キナーゼ(PMVK)タンパク質またはそれをコーディングする遺伝子を有効成分として含む癌患者の放射線治療予後予測用バイオマーカー組成物。
- 前記癌は、肺癌または膵臓癌であることを特徴とする請求項7に記載の癌患者の放射線治療予後予測用バイオマーカー組成物。
- PMVKの発現レベルを測定することができる製剤を有効成分として含む癌患者の放射線治療予後予測用組成物。
- 前記PMVKの発現レベルを測定することができる製剤は、前記PMVK遺伝子に特異的に結合するプライマーまたはプローブ、前記PMVKタンパク質に特異的に結合する抗体、ペプチド、アプタマーまたは化合物であることを特徴とする請求項9に記載の癌患者の放射線治療予後予測用組成物。
- 前記癌は、肺癌または膵臓癌であることを特徴とする請求項9に記載の癌患者の放射線治療予後予測用組成物。
- 請求項9から請求項11のうち何れか一項に記載の組成物を含む癌患者の放射線治療予後予測用キット。
- ホスホメバロン酸キナーゼ(PMVK)タンパク質の発現または活性抑制剤を有効成分として含む癌細胞に対する放射線敏感性増進用薬学組成物。
- 前記PMVK発現抑制剤は、PMVK遺伝子のmRNAに相補的に結合するアンチセンスヌクレオチド、小さな干渉RNA(siRNA)及び短ヘアピンRNA(shRNA)で構成された群から選択された何れか1つであることを特徴とする請求項13に記載の癌細胞に対する放射線敏感性増進用薬学組成物。
- 前記PMVK活性抑制剤は、PMVKタンパク質に特異的に結合する低分子化合物、ペプチド、ペプチドミメティクス、アプタマー、抗体、及び天然物で構成された群から選択された何れか1つであることを特徴とする請求項13に記載の癌細胞に対する放射線敏感性増進用薬学組成物。
- 前記癌細胞は、肺癌細胞または膵臓癌細胞であることを特徴とする請求項13から請求項15のうち何れか一項に記載の癌細胞に対する放射線敏感性増進用薬学組成物。
- (1)癌患者から分離された試料からPMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを測定する段階と、
(2)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを対照群試料と比較する段階と、
(3)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルが対照群試料よりも高い場合、放射線抵抗性癌であると判断する段階と、
を含む放射線抵抗性癌診断に必要な情報を提供する方法。 - (1)癌患者から分離された試料からPMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを測定する段階と、
(2)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを対照群試料と比較する段階と、
(3)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルが対照群試料よりも高い場合、放射線治療予後が良くないと判断する段階と、
を含む癌患者の放射線治療予後予測に必要な情報を提供する方法。 - (1)癌細胞に試験物質を接触させる段階と、
(2)前記試験物質を接触した癌細胞でPMVKタンパク質の発現または活性程度を測定する段階と、
(3)対照群試料と比較して、前記PMVKタンパク質の発現または活性程度が減少した試験物質を選別する段階と、
を含む癌細胞に対する放射線敏感性増進剤スクリーニング方法。 - 放射線抵抗性癌診断のためのバイオマーカーであって、PMVKタンパク質またはそれをコーディングする遺伝子の用途。
- 放射線抵抗性癌診断のためのPMVKの発現レベルを測定することができる製剤の用途。
- 癌患者の放射線治療予後予測のためのバイオマーカーであって、PMVKタンパク質またはそれをコーディングする遺伝子の用途。
- 癌患者の放射線治療予後予測のためのPMVKの発現レベルを測定することができる製剤の用途。
- 癌細胞に対する放射線敏感性の増進のための薬剤を製造するためのPMVKタンパク質の発現または活性抑制剤の用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021111826A JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0156320 | 2017-11-22 | ||
KR20170156320 | 2017-11-22 | ||
KR10-2018-0143493 | 2018-11-20 | ||
KR1020180143493A KR102141997B1 (ko) | 2017-11-22 | 2018-11-20 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
PCT/KR2018/014363 WO2019103456A2 (ko) | 2017-11-22 | 2018-11-21 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021111826A Division JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021504726A true JP2021504726A (ja) | 2021-02-15 |
JP6924907B2 JP6924907B2 (ja) | 2021-08-25 |
Family
ID=66675714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020546259A Active JP6924907B2 (ja) | 2017-11-22 | 2018-11-21 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
JP2021111826A Active JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021111826A Active JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11674184B2 (ja) |
EP (1) | EP3715475A4 (ja) |
JP (2) | JP6924907B2 (ja) |
KR (1) | KR102141997B1 (ja) |
CN (1) | CN111630185A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7392702B2 (ja) | 2021-10-28 | 2023-12-06 | トヨタ自動車株式会社 | 車両側部構造 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013511999A (ja) * | 2009-12-01 | 2013-04-11 | プレシジョン セラピューティクス,インコーポレイテッド | 乳癌細胞についての多剤応答マーカー |
US20140363816A1 (en) * | 2011-12-22 | 2014-12-11 | The Regents Of The University Of Colorado, A Body Corporate | Methods for prediction of clinical response to radiation therapy in cancer patients |
JP2016521966A (ja) * | 2013-03-15 | 2016-07-28 | メタマーク ジェネティクス, インコーポレイテッド | 癌の予後のための組成物および方法 |
US20160313302A1 (en) * | 2014-09-10 | 2016-10-27 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005067391A2 (en) * | 2004-01-19 | 2005-07-28 | Technion Research & Development Foundation Ltd. | Diagnostic test for parkinson's disease |
US20070105133A1 (en) | 2005-06-13 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US8093000B2 (en) * | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
EP2625294A4 (en) * | 2010-10-07 | 2014-03-26 | Univ Columbia | METHOD OF TREATING CANCER WITH P53 MUTATION |
KR101432174B1 (ko) | 2013-01-22 | 2014-08-22 | 한국원자력의학원 | Cdc27을 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도 |
FR3013484B1 (fr) * | 2013-11-19 | 2018-03-23 | Idemia France | Carte a microcircuit contenant de multiples cartes predecoupees ayant une meme plage de contacts |
CA2968359A1 (en) | 2014-12-23 | 2016-06-30 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
WO2017104912A1 (ko) | 2015-12-15 | 2017-06-22 | 한국원자력의학원 | 방사선 저항성 진단용 조성물 및 이의 용도 |
CA3072087A1 (en) * | 2017-08-11 | 2019-02-14 | Board Of Regents, The University Of Texas System | Targeting kinases for the treatment of cancer metastasis |
-
2018
- 2018-11-20 KR KR1020180143493A patent/KR102141997B1/ko active IP Right Grant
- 2018-11-21 CN CN201880087275.XA patent/CN111630185A/zh active Pending
- 2018-11-21 EP EP18881259.8A patent/EP3715475A4/en active Pending
- 2018-11-21 US US16/766,297 patent/US11674184B2/en active Active
- 2018-11-21 JP JP2020546259A patent/JP6924907B2/ja active Active
-
2021
- 2021-07-05 JP JP2021111826A patent/JP7167263B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013511999A (ja) * | 2009-12-01 | 2013-04-11 | プレシジョン セラピューティクス,インコーポレイテッド | 乳癌細胞についての多剤応答マーカー |
US20140363816A1 (en) * | 2011-12-22 | 2014-12-11 | The Regents Of The University Of Colorado, A Body Corporate | Methods for prediction of clinical response to radiation therapy in cancer patients |
JP2016521966A (ja) * | 2013-03-15 | 2016-07-28 | メタマーク ジェネティクス, インコーポレイテッド | 癌の予後のための組成物および方法 |
US20160313302A1 (en) * | 2014-09-10 | 2016-10-27 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
Non-Patent Citations (2)
Title |
---|
HWANG, K. ET AL.: "Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 123, no. 8, JPN6021012058, 13 August 2008 (2008-08-13), pages 1807 - 1815, XP071284975, ISSN: 0004477579, DOI: 10.1002/ijc.23672 * |
LONG, X. ET AL.: "Dose-dependent expression changes of early response genes to ionizing radiation in human lymphoblast", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 19, no. 4, JPN6021012055, 1 April 2007 (2007-04-01), pages 607 - 615, ISSN: 0004477578 * |
Also Published As
Publication number | Publication date |
---|---|
JP2021176852A (ja) | 2021-11-11 |
CN111630185A (zh) | 2020-09-04 |
JP6924907B2 (ja) | 2021-08-25 |
EP3715475A2 (en) | 2020-09-30 |
KR20190059237A (ko) | 2019-05-30 |
US11674184B2 (en) | 2023-06-13 |
JP7167263B2 (ja) | 2022-11-08 |
KR102141997B1 (ko) | 2020-08-06 |
US20210025007A1 (en) | 2021-01-28 |
EP3715475A4 (en) | 2021-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Baldassarre et al. | Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers | |
KR20110036610A (ko) | 신규 온코진 nrf2 | |
Lv et al. | LncRNA PINK1-AS promotes Gαi1-driven gastric cancer tumorigenesis by sponging microRNA-200a | |
EP2611933A1 (en) | Method for the prognosis of the progression of cancer | |
KR101925125B1 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
JP2017511812A (ja) | 受容体共役タンパク質キナーゼ−3(rip3)発現促進剤を有効成分として含む抗癌補助用組成物、受容体共役タンパク質キナーゼ−3(rip3)の発現を促して抗癌剤感受性を増進させる抗癌補助剤のスクリーニング方法及び抗癌剤感受性のモニターリング方法 | |
KR101315570B1 (ko) | 간암 진단 마커 및 치료제로서의 nlk | |
JP7167263B2 (ja) | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 | |
CA2706075A1 (en) | Cancer diagnostic and therapeutic methods that target plk4/sak | |
US11510911B2 (en) | Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor | |
KR101952649B1 (ko) | Lrp-1을 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 | |
US9084775B2 (en) | Methods for diagnosing and treating neuroendocrine cancer | |
KR101943157B1 (ko) | 유방암 예후 예측용 바이오마커 | |
KR102238520B1 (ko) | Fes 저해제를 포함하는 방사선 민감도 증진용 조성물 | |
KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 | |
WO2019103456A2 (ko) | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 | |
JP7012363B2 (ja) | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー | |
JP7221050B2 (ja) | Plrg1(pleiotropic regulator 1)抑制剤を含む癌治療用組成物 | |
KR101821455B1 (ko) | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 | |
US20210164982A1 (en) | Pharmaceutical use of actinin-4 involved in induction of cervical cancer | |
US8415109B2 (en) | Methods for diagnosing and treating neuroendocrine cancer | |
WO2005120520A2 (en) | Compositions and methods for diagnosis and treatment of chemotherapy-resistant neoplastic disease | |
KR20230010414A (ko) | Csde1을 유효성분으로 포함하는 삼중음성유방암 전이 예측용 바이오마커 조성물 | |
Shen et al. | CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2/STAT3 signaling pathway | |
WO2014129895A1 (en) | Means and method for increasing the sensitivity of cancers for radiotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210705 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210713 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210802 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6924907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |